GD2-CART01 for Relapsed or Refractory High-Risk Neuroblastoma.
Francesca Del BufaloBiagio De AngelisIgnazio CaruanaGiada Del BaldoMaria Antonietta De IorisAnnalisa SerraAngela MastronuzziMaria G CefaloDaria PagliaraMatteo AmicucciGiuseppina Li PiraGiovanna LeoneValentina BertainaMatilde SinibaldiStefano Di CeccaMarika GuercioZeinab AbbaszadehLaura IaffaldanoMonica GunettiStefano IacovelliRossana BugianesiStefania MacchiaMattia AlgeriPietro MerliFederica GalavernaRachid AbbasMaria C GarganeseMaria F VillaniGiovanna S ColafatiFederico BonettiMarco RabusinKatia PerruccioVeronica FolsiConcetta QuintarelliFranco Locatellinull nullPublished in: The New England journal of medicine (2023)
The use of GD2-CART01 was feasible and safe in treating high-risk neuroblastoma. Treatment-related toxic effects developed, and the activation of the suicide gene controlled side effects. GD2-CART01 may have a sustained antitumor effect. (Funded by the Italian Medicines Agency and others; ClinicalTrials.gov number, NCT03373097.).